A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers

Journal of Pathology

Volumn 227, Issue 1, 2012, Pages 29-41

  Natrajan, Rachael ^a   Mackay, Alan ^a   Lambros, Maryou B ^a   Weigelt, Britta ^b   Wilkerson, Paul M ^a   Manie, Elodie ^c   Grigoriadis, Anita ^d   A'Hern, Roger ^a   Van Der Groep, Petra ^e   Kozarewa, Iwanka ^a   Popova, Tatiana ^c   Mariani, Odette ^f   Turajlic, Samra ^a   Furney, Simon J ^a   Marais, Richard ^a   Rodruigues, Daniel Nava ^a   Flora, Adriana C ^a   Wai, Patty ^a   Pawar, Vidya ^a   McDade, Simon ^g   Carroll, Jason ^h   Stoppa Lyonnet, Dominique ^c,f   Green, Andrew R ⁱ   Ellis, Ian O ⁱ   Swanton, Charles ^b,j   Van Diest, Paul ^e   Delattre, Olivier ^c   Lord, Christopher J ^a   Foulkes, William D ^k   Vincent Salomon, Anne ^c,f   Ashworth, Alan ^a   Stern, Marc Henri ^c,f   Reis Filho, Jorge S ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c INSTITUT CURIE   (France)

^d GUY S HOSPITAL   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f INSTITUT CURIE   (France)

^g QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^h CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

ⁱ NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k MCGILL UNIVERSITY   (Canada)

more..

Author keywords

BRCA1; Breast cancer; Mutation; Next generation sequencing; Tumour suppressor genes

Indexed keywords

BRCA1 PROTEIN; COMPLEMENTARY DNA; DNA; ESTROGEN RECEPTOR; RNA;

ADULT; ARTICLE; BREAST CANCER; CASE REPORT; DNA REPAIR; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENOME; HUMAN; HUMAN CELL; LYMPHOCYTE; MASSIVELY PARALLEL SEQUENCING; MICROARRAY ANALYSIS; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR CELL; TUMOR GENE; TUMOR SUPPRESSOR GENE;

APOPTOSIS REGULATORY PROTEINS; BRCA1 PROTEIN; BREAST NEOPLASMS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CARCINOMA, DUCTAL, BREAST; DNA MUTATIONAL ANALYSIS; DNA REPAIR-DEFICIENCY DISORDERS; DNA, NEOPLASM; FEMALE; GATA4 TRANSCRIPTION FACTOR; GENOMICS; GERM-LINE MUTATION; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53; VESICULAR TRANSPORT PROTEINS;

EID: 84859628102     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4003     Document Type: Article

References (78)

1. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nature Rev Cancer 2004; 4: 665-676. (Pubitemid 39215065)
2. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006; 25: 5854-5863. (Pubitemid 44453441)
3. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006; 25: 5846-5853. (Pubitemid 44453440)
4. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
5. Hosey AM, Gorski JJ, Murray MM, et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 2007; 99: 1683-1694. (Pubitemid 351767217)
6. Gorski JJ, Kennedy RD, Hosey AM, et al. The complex relationship between BRCA1 and ERalpha in hereditary breast cancer. Clin Cancer Res 2009; 15: 1514-1518.
7. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Med 2009; 15: 907-913.
8. Molyneux G, Geyer FC, Magnay FA, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010; 7: 403-417.
9. Vaziri SA, Krumroy LM, Elson P, et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 2001; 7: 1937-1945. (Pubitemid 32994828)
10. Tung N, Wang Y, Collins LC, et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res 2010; 12: R12.
11. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006; 25: 5864-5874. (Pubitemid 44453442)
12. Guirouilh-Barbat J, Huck S, Bertrand P, et al. Impact of the KU80 pathway on NHEJ-induced genome rearrangements in mammalian cells. Mol Cell 2004; 14: 611-623. (Pubitemid 38744575)
13. McVey M, Lee SE. MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. Trends Genet 2008; 24: 529-538.
14. Barber LJ, Rosa Rosa JM, Kozarewa I, et al. Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer. PLoS One 2011; 6: e21639.
15. Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869-873.
16. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
17. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-813.
18. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009; 15: 2711-2722.
19. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006; 10: 529-541. (Pubitemid 44854748)
20. Jonsson G, Staaf J, Vallon-Christersson J, et al. Genomic sub-types of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 2010; 12: R42.
21. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462: 1005-1010.
22. Manie E, Vincent-Salomon A, Lehmann-Che J, et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009; 69: 663-671.
23. Drmanac R, Sparks AB, Callow MJ, et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 2010; 327: 78-81.
24. Lee W, Jiang Z, Liu J, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010; 465: 473-477.
25. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/ Map format and SAMtools. Bioinformatics 2009; 25: 2078-2079.
26. Popova T, Manie E, Stoppa-Lyonnet D, et al. Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol 2009; 10: R128.
27. Natrajan R, Weigelt B, Mackay A, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010; 121: 575-589.
28. Weigelt B, Mackay A, A'Hern R, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010; 11: 339-349.
29. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96.
30. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
31. Geyer FC, Lacroix-Triki M, Savage K, et al. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 2011; 24: 209-231.
32. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007; 23: 657-663. (Pubitemid 46554715)
33. Joosse SA, Brandwijk KI, Mulder L, et al. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosomes Cancer 2011; 50: 71-81.
34. Joosse SA, van Beers EH, Tielen IH, et al. Prediction of BRCA1- association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat 2009; 116: 479-489.
35. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003; 31: 3812-3814. (Pubitemid 37442253)
36. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002; 30: 3894-3900. (Pubitemid 35012462)
37. Gonzalez-Perez A, Lopez-Bigas N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet 2011; 88: 440-449.
38. Kaminker JS, Zhang Y, Watanabe C, et al. CanPredict: a computational tool for predicting cancer-associated missense mutations. Nucleic Acids Res 2007; 35: W595-W598.
39. Stephens P, Edkins S, Davies H, et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nature Genet 2005; 37: 590-592. (Pubitemid 40770413)
40. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274. (Pubitemid 44571966)
41. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113. (Pubitemid 350134889)
42. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463: 191-196.
43. Hicks J, Krasnitz A, Lakshmi B, et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 2006; 16: 1465-1479. (Pubitemid 44878486)
44. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 2011; 145: 30-38.
45. Pleasance ED, Stephens PJ, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463: 184-190.
46. Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011; 331: 435-439.
47. Natrajan R, Lambros MB, Geyer FC, et al. Loss of 16q in high grade breast cancer is associated with estrogen receptor status: evidence for progression in tumors with a luminal phenotype? Genes Chromosomes Cancer 2009; 48: 351-365.
48. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011; 144: 27-40.
49. Ross-Innes CS, Stark R, Teschendorff AE, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012; 481: 389-393.
50. Ha KC, Lalonde E, Li L, et al. Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. BMC Med Genomics 2011; 4: 75.
51. Robinson DR, Kalyana-Sundaram S, Wu YM, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Med 2011; 17: 1646-1651.
52. Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010; 16: 6159-6168.
53. Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature 2010; 463: 893-898.
54. Tung N, Miron A, Schnitt SJ, et al. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res 2010; 12: R95.
55. Biggs PJ, Warren W, Venitt S, et al. Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unravelling the aetiology of cancer. Mutagenesis 1993; 8: 275-283. (Pubitemid 23226768)
56. Jonsson G, Naylor TL, Vallon-Christersson J, et al. Distinct genomic profiles in hereditary breast tumors identified by arraybased comparative genomic hybridization. Cancer Res 2005; 65: 7612-7621. (Pubitemid 41297233)
57. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450: 893-898. (Pubitemid 350231325)
58. Nancarrow DJ, Handoko HY, Smithers BM, et al. Genome-wide copy number analysis in esophageal adenocarcinoma using highdensity single-nucleotide polymorphism arrays. Cancer Res 2008; 68: 4163-4172.
59. Exil VJ, Silva Avila D, Benedetto A, et al. Stressed-induced TMEM135 protein is part of a conserved genetic network involved in fat storage and longevity regulation in Caenorhabditis elegans. PLoS One 2010; 5: e14228.
60. Teraoka SN, Bernstein JL, Reiner AS, et al. Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study. Breast Cancer Res 2011; 13: R114.
61. Brognard J, Zhang YW, Puto LA, et al. Cancer-associated loss-of- function mutations implicate DAPK3 as a tumor-suppressing kinase. Cancer Res 2011; 71: 3152-3161.
62. Agnihotri S, Wolf A, Munoz DM, et al. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J Exp Med 2011; 208: 689-702.
63. Hellebrekers DM, Lentjes MH, van den Bosch SM, et al. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res 2009; 15: 3990-3997.
64. Wen XZ, Akiyama Y, Pan KF, et al. Methylation of GATA-4 and GATA-5 and development of sporadic gastric carcinomas. World J Gastroenterol 2010; 16: 1201-1208.
65. Grigoriadis A, Oliver GR, Tanney A, et al. Identification of differentially expressed sense and antisense transcript pairs in breast epithelial tissues. BMC Genomics 2009; 10: 324.
66. Stender JD, Kim K, Charn TH, et al. Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol 2010; 30: 3943-3955.
67. Gu J, Ajani JA, Hawk ET, et al. Genome-wide catalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Philadelphia) 2010; 3: 1176-1186.
68. Steensma DP, Gibbons RJ, Mesa RA, et al. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol 2005; 74: 47-53. (Pubitemid 40143686)
69. Silva FP, Morolli B, Storlazzi CT, et al. Identification of RUNX1/AML1 as a classical tumor suppressor gene. Oncogene 2003; 22: 538-547. (Pubitemid 36188611)
70. Saal LH, Gruvberger-Saal SK, Persson C, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nature Genet 2008; 40: 102-107.
71. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009. (Pubitemid 35461656)
72. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679. (Pubitemid 40260888)
73. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007; 13: 3207-3214. (Pubitemid 46944903)
74. Garg V, Kathiriya IS, Barnes R, et al. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 2003; 424: 443-447. (Pubitemid 36917494)
75. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet 1995; 11: 210-212.
76. Brenner AJ, Paladugu A, Wang H, et al. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. Clin Cancer Res 1996; 2: 1993-1998.
77. Silva J, Silva JM, Dominguez G, et al. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Pathol 2003; 199: 289-297. (Pubitemid 36266851)
78. Quesnel B, Fenaux P, Philippe N, et al. Analysis of p16 gene deletion and point mutation in breast carcinoma. Br J Cancer 1995; 72: 351-353.